Marieke van Son

173 RE-SALVAGE FOCAL HDR-BT REFERENCES 1. Mottet N, Bellmunt J, Bolla M, et al.: EAU-ESTRO-SIOG guidelines on pros- tate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017, 71:618-629. 10.1016/j. eururo.2016.08.003 2. Zaorsky NG, Keith SW, Shaikh T, et al.: Impact of radiation therapy dose esca- lation on prostate cancer outcomes and toxicities. Am J Clin Oncol. 2016, 41:409- 415. 10.1097/COC.0000000000000285 3. James ND, Spears MR, Clarke NW, et al.: Survival with newly diagnosed metastat- ic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015, 67:1028- 1038. 10.1016/j.eururo.2014.09.032 4. Golbari NM, Katz AE: Salvage therapy options for local prostate cancer recur- rence after primary radiotherapy: a liter- ature review. Curr Urol Rep. 2017, 18:63. 10.1007/s11934-017-0709-4 5. Ahmed HU: The index lesion and the origin of prostate cancer . N Engl J Med. 2009, 361:1704-1706. 10.1056/NEJMci- br0905562 6. Pucar D, Hricak H, Shukla-Dave A, et al.: Clinically significant prostate cancer local recurrence after radiation thera- py occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007, 69:62- 69.10.1016/j.ijrobp.2007.03.065 7. Holly R, Morton GC, Sankreacha R, et al: Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachyther- apy. 2011, 10:299–305.10.1016/j. brachy.2010.11.007 8. Claren A, Gautier M, Feuillade J, Falk AT, Levi JM: Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: a case report. J Contemp Brachytherapy. 2015, 7:244-247. 10.5114/jcb.2015.51852 9. Maenhout M, van Vulpen M, Moerland M, et al.: Second salvage high-dose-rate brachytherapy for radiorecurrent pros- tate cancer. J Contemp Brachytherapy. 2017, 9:161-166.10.5114/jcb.2017.67015 10. Peters M, Kanthabalan A, Shah TT, et al. : Development and internal validation of prediction models for biochemical fail- ure and composite failure after focal sal- vage high intensity focused ultrasound for local radiorecurrent prostate cancer: presentation of risk scores for individu- al patient prognoses. Urol Oncol. 2018, 36:11-13. 10.1016/j.urolonc.2017.08.022 9